K
Kenneth A. Bauer
Researcher at Beth Israel Deaconess Medical Center
Publications - 280
Citations - 25949
Kenneth A. Bauer is an academic researcher from Beth Israel Deaconess Medical Center. The author has contributed to research in topics: Fondaparinux & Thrombin. The author has an hindex of 76, co-authored 277 publications receiving 23364 citations. Previous affiliations of Kenneth A. Bauer include Dana Corporation & Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
Extrapulmonary manifestations of COVID-19.
Aakriti Gupta,Aakriti Gupta,Mahesh V. Madhavan,Kartik Sehgal,Kartik Sehgal,Nandini Nair,Shiwani Mahajan,Tejasav S. Sehrawat,Behnood Bikdeli,Behnood Bikdeli,Neha Ahluwalia,John C. Ausiello,Elaine Wan,Daniel E. Freedberg,Ajay J. Kirtane,Sahil A. Parikh,Mathew S. Maurer,Anna S. Nordvig,Domenico Accili,Joan M. Bathon,Sumit Mohan,Kenneth A. Bauer,Kenneth A. Bauer,Martin B. Leon,Harlan M. Krumholz,Nir Uriel,Mandeep R. Mehra,Mitchell S.V. Elkind,Mitchell S.V. Elkind,Gregg W. Stone,Allan Schwartz,David D. Ho,John P. Bilezikian,Donald W. Landry +33 more
TL;DR: The extrapulmonary organ-specific pathophysiology, presentations and management considerations for patients with COVID-19 are reviewed to aid clinicians and scientists in recognizing and monitoring the spectrum of manifestations, and in developing research priorities and therapeutic strategies for all organ systems involved.
Journal ArticleDOI
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis.
John Danesh,Sarah Lewington,Simon G. Thompson,Lowe Gdo.,Rory Collins,John B. Kostis,Angela Wilson,Aaron R. Folsom,K. Wu,M. Benderly,Uri Goldbourt,Johann Willeit,Stefan Kiechl,Yarnell Jwg.,P. M. Sweetnam,P. Elwood,Mary Cushman,Bruce M. Psaty,Russell P. Tracy,Anne Tybjærg-Hansen,F. Haverkate,De Maat Mpm.,Fowkes Fgr.,Amanda J Lee,F.B. Smith,Veikko Salomaa,Kennet Harald,V. Rasi,E. Vahtera,P. Jousilahti,Juha Pekkanen,Ralph B. D'Agostino,W B Kannel,Wilson Pwf.,Geoffrey H. Tofler,Carmen Luisa Arocha-Piñango,Alvaro Rodríguez-Larralde,Elena Nagy,Mercedes E Mijares,Raul Espinosa,E Rodriquez-Roa,Elena Ryder,María Diez-Ewald,Gilberto Campos,Virginia Fernández,Enrique Torres,Roberto Marchioli,Franco Valagussa,Annika Rosengren,Lars Wilhelmsen,Georgios Lappas,Henry Eriksson,Peter Cremer,Dorothea Nagel,J D Curb,Beatriz L. Rodriguez,K Yano,Jukka T. Salonen,Kristiina Nyyssönen,Tomi-Pekka Tuomainen,Bo Hedblad,P. Lind,H. Loewel,Wolfgang Koenig,Tom W. Meade,J.A. Cooper,B L De Stavola,C. Knottenbelt,George J. Miller,Kenneth A. Bauer,Robert D. Rosenberg,S. Sato,A. Kitamura,Yoshihiko Naito,Hiroyasu Iso,T. Palosuo,Pierre Ducimetière,Philippe Amouyel,Dominique Arveiler,Alun Evans,Jean Ferrières,Irène Juhan-Vague,Annie Bingham,Helmut Schulte,Gerd Assmann,Bernard Cantin,Benoît Lamarche,Jean-Pierre Després,Gilles R. Dagenais,Hugh Tunstall-Pedoe,Mark Woodward,Yoav Ben-Shlomo +91 more
TL;DR: In this article, a large-scale individual participant meta-analysis was conducted to assess the relationship of fibrinogen levels with risk of major vascular and non-vascular outcomes based on individual participant data.
Journal ArticleDOI
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial
Alexander G.G. Turpie,Michael R. Lassen,Bruce L. Davidson,Kenneth A. Bauer,Michael Gent,Louis M. Kwong,Fred D. Cushner,Paul A. Lotke,Scott D. Berkowitz,Tiemo J. Bandel,Alice Benson,Frank Misselwitz,William D. Fisher +12 more
TL;DR: Oral rivaroxaban 10 mg once daily for 10-14 days was significantly superior to subcutaneous enoxaparin 30 mg given every 12 h for the prevention of venous thromboembolism after total knee arthroplasty.
Journal ArticleDOI
Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Paul M. Ridker,Samuel Z. Goldhaber,Ellie Danielson,Yves Rosenberg,Charles S. Eby,Steven R. Deitcher,Mary Cushman,Stephan Moll,Craig M. Kessler,C. Gregory Elliott,Rolf Paulson,Turnly Wong,Kenneth A. Bauer,Bruce A. Schwartz,Joseph P. Miletich,Henri Bounameaux,Robert J. Glynn +16 more
TL;DR: Long-term, low-intensity warfarin therapy is a highly effective method of preventing recurrent venous thromboembolism.
Journal ArticleDOI
Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.
TL;DR: In patients undergoing orthopedic surgery, 2.5 mg of fondaparinux sodium once daily, starting 6 hours postoperatively, showed a major benefit over enoxaparin, achieving an overall risk reduction of VTE greater than 50% without increasing the risk of clinically relevant bleeding.